Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26726102 | 0.82 | — | — | |
| SCHEMBL22029654 | 0.81 | — | — | |
| SCHEMBL22029723 | 0.81 | — | — | |
| SCHEMBL22029773 | 0.79 | CA1 (0.49) | CA1CA2CA9CA7 | |
| SCHEMBL22029775 | 0.79 | CA1 (0.49) | CA1CA2CA9CA7 | |
| SCHEMBL22029684 | 0.76 | CA1 (0.33) | CA1CA2CA9CA7 | |
| SCHEMBL22029823 | 0.76 | CA1 (0.33) | CA1CA2CA9CA7 | |
| SCHEMBL9769079 | 0.76 | CA1 (0.37) | CA1CA2CA9CA7 | |
| SCHEMBL32668867 | 0.74 | — | — | |
| SCHEMBL32668675 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9169280-B2 | Methods for the synthesis of plasmalogens and plasmalogen derivatives, and therapeutic uses thereof | PHENOMENOME DISCOVERIES INC. (CA) | 2015-10-27 | — | — | US | disclosed |
| US-9169280-B2 | Methods for the synthesis of plasmalogens and plasmalogen derivatives, and therapeutic uses thereof | PHENOMENOME DISCOVERIES INC. (CA) | 2015-10-27 | — | — | US | disclosed |
| US-9169280-B2 | Methods for the synthesis of plasmalogens and plasmalogen derivatives, and therapeutic uses thereof | PHENOMENOME DISCOVERIES INC. (CA) | 2015-10-27 | — | — | US | disclosed |
| US-9006472-B2 | Methods for the synthesis of 13C labeled plasmalogen | PHENOMENOME DISCOVERIES INC. (CA) | 2015-04-14 | — | — | US | disclosed |
| US-20140323749-A1 | METHODS FOR THE SYNTHESIS OF 13C LABELED PLASMALOGEN | MED-LIFE DISCOVERIES LP (CA) | 2014-10-30 | — | — | US | disclosed |
| US-20140323749-A1 | METHODS FOR THE SYNTHESIS OF 13C LABELED PLASMALOGEN | MED-LIFE DISCOVERIES LP (CA) | 2014-10-30 | — | — | US | disclosed |
| US-20140296187-A1 | METHODS FOR THE SYNTHESIS OF PLASMALOGENS AND PLASMALOGEN DERIVATIVES, AND THERAPEUTIC USES THEREOF | MED-LIFE DISCOVERIES LP (CA) | 2014-10-02 | — | — | US | disclosed |
| US-20140296187-A1 | METHODS FOR THE SYNTHESIS OF PLASMALOGENS AND PLASMALOGEN DERIVATIVES, AND THERAPEUTIC USES THEREOF | MED-LIFE DISCOVERIES LP (CA) | 2014-10-02 | — | — | US | disclosed |
| US-20140296187-A1 | METHODS FOR THE SYNTHESIS OF PLASMALOGENS AND PLASMALOGEN DERIVATIVES, AND THERAPEUTIC USES THEREOF | MED-LIFE DISCOVERIES LP (CA) | 2014-10-02 | — | — | US | disclosed |
| WO-2013183683-A1 | LIQUID-CRYSTAL COMPOSITION | DIC株式会社 (JP) | 2013-12-12 | — | — | WO | disclosed |
| WO-2013183684-A1 | LIQUID-CRYSTAL OPTICAL MODULATION ELEMENT | DIC株式会社 (JP) | 2013-12-12 | — | — | WO | disclosed |
| WO-2013073613-A1 | LIQUID CRYSTAL DISPLAY ELEMENT | DIC株式会社 (JP) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013071418-A1 | METHODS FOR THE SYNTHESIS OF PLASMALOGENS AND PLASMALOGEN DERIVATIVES, AND THERAPEUTIC USES THEREOF | PHENOMENOME DISCOVERIES INC. (CA) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323749-A1 | METHODS FOR THE SYNTHESIS OF 13C LABELED PLASMALOGEN | PLPBP, SGMS2, PCCA | CA1 2487/4885CA2 2686/4885CA9 3529/4885 |
| US-20140296187-A1 | METHODS FOR THE SYNTHESIS OF PLASMALOGENS AND PLASMALOGEN DERIVATIVES, AND THERAPEUTIC USES THEREOF | FASN, SGMS2, ALOX12 | CA1 3776/4885CA2 3848/4885CA9 4473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.